Compare...

 

Dr. Dan Barouch, who runs the virology center at Beth Israel and led the study, presented the data to the FDA’s 
Antibody responses from the two-shot Pfizer and Moderna messenger RNA vaccines peaked after full vaccination, and then began to decline six months later.

The researchers found the decline continued after eight months. While Johnson & Johnson’s one-shot vaccine produced a much lower initial antibody response, it remained “relatively stable” for the eight months observed, with “minimal-to-no evidence of decline,” according to the study.

Two to four weeks after vaccination, the researchers found the median live-neutralizing antibody titer for the Pfizer and Moderna vaccines to be about 1,790 and 5,850, respectively. But after eight months, those figures declined by 34- and 44-fold, and the trend was similar with other antibody measures.
Barouch’s lab also looked at T cell responses and found those responses were stable over time, for all three vaccines.

The median levels of virus-fighting antibodies for the Johnson & Johnson shot were initially about 150 — much lower than the mRNA vaccines — but then it jumped to about 630 after eight months.

Beth Israel codeveloped the Johnson & Johnson vaccine alongside the New Jersey-based pharmaceutical giant.

So what to choose for the most vulnerable?   Just a thought.